Currently, numerous studies targeting KRAS are being investigated in different stages of pre-clinical and clinical study, such as Sotorasib, Adagrasib, Selumetinib, and Trametinib, and future trials should determine the value of KRAS inhibitors in ICC [67]. Here, KRAS is linked to intrahepatic cholangiocarcinoma.